Effects of D-002, a product isolated from beeswax, on gastric symptoms of patients with osteoarthritis treated with piroxicam: A pilot study

Journal of Medicinal Food

Volumn 8, Issue 1, 2005, Pages 63-68

  Illnait, José ^a   Terry, Héctor ^b   Más, Rosa ^a   Fernández, Lilia ^a   Carbajal, D ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Plaza Veterans House ^*  (Cuba)

Author keywords

Beeswax alcohols; D 002; Non steroidal anti inflammatory drug induced gastric disturbances; Non steroidal anti inflammatory drug related adverse effects; Piroxicam

Indexed keywords

ALCOHOL DERIVATIVE; ANTIULCER AGENT; D 002; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROPOLIS; TRIACONTANOL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BITTER TASTE; CELL PROTECTION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEARTBURN; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OSTEOARTHRITIS; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISEASE; STOMACH MUCUS; STOMACH PH; TASTE DISORDER;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FATTY ALCOHOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PILOT PROJECTS; PIROXICAM; STOMACH ULCER; TREATMENT OUTCOME;

PROPOLIS;

EID: 18144410919     PISSN: 1096620X     EISSN: None     Source Type: Journal    
DOI: 10.1089/jmf.2005.8.63     Document Type: Article

References (39)

1. Tasman-Jones C: Pathogenesis of peptic ulcer disease and gastritis: Importance of aggressive and cytoprotective factors. Scand J Gastroenterol 1986;19(Suppl 22):1-5.
2. Holt S: Proton pump inhibition for acid-related disease. South Med J 1991;84:1078-1087.
3. Felts W, Yelin E: The economic impact of the rheumatic disease in United States. J Rheumatol 1989;16:867-884.
4. Glazier R, Buchbinder R, Beel M: Critical appraisal of continuing medical education in the rheumatic disease for primary care physicians. Arthritis Rheum 1995;38:533-538.
5. Aly A: NSAID induced ulcer and its complications. Nord Med 1997;112:195-197.
6. Di Mario F, Battaglia G, Pasqualetti P, et al.: Long-term treatment for gastric and duodenal ulcer. Ital J Gastroenterol 1990;22(Suppl 2):24-28.
7. Wilde MI, McTavish D: Omeprazole: An update of its pharmacology and therapeutic use in acid-related disorders. Drugs 1994;48:91-132.
8. Spencer CM, Faulds D: Lansoprazole: A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994;48:404-430.
9. Hawkey CJ: Management of gastroduodenal ulcer caused by non-steroidal anti-inflammatory drugs. Baillieres Best Pract Res Clin Gastroenterol 2000;14:173-192.
10. G.I.S.U. (Interdisciplinary Group for Ulcer Study): Long-term treatment of patients with gastric ulcer: Sucralfate versus ranitidine versus no treatment: An interim report at the end of year 1 of a 3-year multicenter, randomized study. Curr Ther Res Clin Exp 1994;55:1117-1126.
11. Mas R: D-002: A product obtained from beeswax. Drugs Future (in press).
12. Carbajal D, Molina V, Valdés S, et al.: Anti-ulcer activity of higher primary alcohols of beeswax. J Pharm Pharmacol 1995;47:731-733.
13. Carbajal D, Molina V, Valdés S, et al.: Possible cytoprotective mechanism in rats of D-002, an anti-ulcerogenic product isolated from beeswax. J Pharm Pharmacol 1996;48:858-860.
14. Slomiany BL, Slomiany A: Role of mucus in gastric mucosal protection. J Physiol Pharmacol 1991;42:147-161.
15. Carbajal D, Molina V, Noa M, et al: Effect of D-002 on gastric mucus composition in ethanol-induced ulcer. Pharmacol Res 2000;42:329-332.
16. Carbajal D, Molina V, Valdés S, et al.: Anti-inflammatory activity of D-002: An active product isolated from beeswax. Prostaglandins Leukot Essent Fatty Acids 1998;59:235-238.
17. Menéndez R, Amor AM, González RM, Jiménez S, Más R: Inhibition of rat microsomal lipid peroxidation by the oral administration of D-002. Braz J Med Biol Res 2000;33:85-90.
18. Molina V, Valdés S, Carbajal D, et al.: Antioxidant effects of D-002 on gastric mucosa of rats with injury induced experimentally. J Med Food 2001;4:79-84.
19. Menéndez R, Mas R, Illnait J, et al.: Effects of D-002 on lipid peroxidation in older subjects. J Med Food 2001;4:71-78.
20. Menéndez R, Mas R, Amor AM, et al.: Effects of D-002 treatment on the susceptibility of whole plasma to in vitro copper-mediated lipid peroxidation, plasma total antioxidant status and plasma thiobarbituric reactive substances in healthy volunteers. Arch Med Res (in press).
21. Shikawa T, Naito Y, Ueda S: Role of oxygen-derived radicals in the pathogenesis of gastric mucosal lesions in rats. J Clin Gastroenterol 1990;12:65-71.
22. Rodeiro I, Alemán C, Noa M, et al.: Preclinical oral toxicology in rats of D-002 a natural drug with antiulcer effects. Drug Chem Toxicol 199;21:151-163.
23. Rodeiro I, Aleman C, Noa M, et al.: Oral toxicological studies of D-002 in mice. Rev CENIC Cien Biol 1999;30:73-75.
24. Aleman C, Rodeiro I, Noa M, et al.: A one year study of D-002. A mixture of aliphatic primary alcohols in Beagle dogs. J Appl Toxicol 2000;20:427-432.
25. Gámez R, Fernández I, Acosta PC, Alemán C, Rodeiro I: Evaluacion mutagénica del D-002 en el ensayo de micron£cleos en médula ¢sea en ratas Sprague Dawley de ambos sexos. Rev CNIC 1999;30:70-72.
26. Rodeiro I, Gámez R, Acosta P, et al.: Estudio genotoxico del D-002, un producto con actividad antiulcerosa. Rev Esp Toxicol 1998;15:117-121.
27. Rodríguez MD, Gámez R, Sánchez M, García H: Developmental toxicity of D-002 a mixture of aliphatic primary alcohols in rats and rabbits. J Appl Toxicol 1998;18:313-316.
28. Hano O, Illnait J, Mas R, et al.: Effects of D-002, a product isolated from beeswax on duodenal ulcer: A double-blinded placebo-controlled study. Curr Ther Res (in press).
29. Salim AS: Removing oxygen-derived free radicals stimulated healing of ethanol-induced erosive gastritis in the rat. Digestion 1990;47:24-28.
30. Salim AS: The significance of removing oxygen-derived free radicals in the treatment of acute and chronic duodenal ulceration in the rat. J Pharm Pharmacol 1990;42:64-67.
31. Vaananen PM, Meddings JB, Wallace JL: Role of oxygen derived free radicals in indomethacin induced gastric injury. Am J Physiol 1991;261:G470-G475.
32. Rastogi L, Patnaik GK, Dikshit M: Free radicals and antioxidant status following pylorus ligation induced gastric mucosal injury in rats. Pharmacol Rex 1998;38:125-132.
33. Takeuchi K, Ueshima K, Hironaka Y, et al.: Oxygen free radicals and lipid peroxidation in the pathogenesis of gastric mucosal lesions induced by indomethacin in rats. Digestion 1991;49:175-184.
34. Yoshikawa T, Veda S, Naito Y, et al.: Role of oxygen-derived free radicals in gastric mucosal injury induced by ischemia reperfusion in rats. Free Radic Res Commun 1989;7:285-291.
35. Tashikazu T, Yukiko M, Hiroshi I: Role of lipid peroxidation and antioxidants in gastric mucosal injury induced by the hypoxanthine-xanthine oxidase system in rats. Free Radic Biol Med 1997;23:243-246.
36. Wada K, Kamisaki Y, Kitano M, et al.: A new gastric ulcer model induced by ischemic-reperfusion in the rat: Role of leukocytes on ulceration in rat stomach. Life Sci 1996;59:295-301.
37. Wallace JL, Granger DN: Pathogenesis of NSAID gastropathy: Are neutrophils the culprits? Trends Pharmacol Sci 1992;13:129-131.
38. Sallingova Z, Kohut A: Pentoxyfylline-associated reduction of indomethacin-induced rat gastric mucosal injury is supported by decreased lipid peroxidation. Physiol Res 1994;43:95-99.
39. 4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-747.